Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma.
[esophageal squamous cell carcinoma]
This
retrospective
analysis
evaluates
the
clinical
efficacy
and
toxicity
of
second
-line
docetaxel-based
chemotherapy
after
failure
of
fluorouracil-based
first
-line
treatment
for
advanced
esophageal
squamous
cell
carcinoma
(
ESCC
)
.
We
retrospectively
reviewed
patients
who
had
received
second
-line
docetaxel-based
chemotherapy
for
advanced
ESCC
in
Zhejiang
Cancer
Hospital
between
January
2008
and
December
2011
.
Survival
curves
were
plotted
using
the
Kaplan-
Meier
method
.
The
Cox
proportional
hazard
model
was
used
for
multivariate
analysis
.
Eighty
-
five
patients
received
docetaxel-based
second
-line
chemotherapy
after
the
failure
of
first
-line
fluorouracil-based
treatment
.
Forty
-
four
patients
received
docetaxel-platinum
chemotherapy
,
and
41
received
docetaxel
single
-
agent
treatment
.
The
progression-free
survival
(
PFS
)
and
overall
survival
(
OS
)
were
3
.
5
and
5
.
5
months
in
all
of
the
patients
,
respectively
.
There
were
no
statistically
significant
differences
in
PFS
and
OS
between
docetaxel-platinum
and
docetaxel
single
-
agent
chemotherapy
groups
(
P-
value
0
.
38
and
0
.
64
,
respectively
)
.
Response
to
first
-line
chemotherapy
was
a
favorable
prognostic
factor
for
PFS
in
uni-
and
multivariate
analyses
(
P-
value
0
.
005
and
0
.
028
,
respectively
)
.
Patients
with
docetaxel-based
second
-line
treatment
obtained
a
moderate
PFS
advantage
in
advanced
ESCC
.
Response
to
first
-line
chemotherapy
was
a
favorable
prognostic
factor
for
PFS
of
second
-line
chemotherapy
in
advanced
ESCC
.